← ANALYST RATINGS · TIPRANKS

Tyra Bioscience (TYRA): analyst forecast and price target

$18.52 −2.73% close 16.10.26 · market cap $1.3B · Healthcare · Biotechnology IWM 0.02%
Price targets and ratings of

Analyst consensus

Strong Buy

11 Buy0 Hold0 Sell

Ratings of 11 analysts in the last 3 months

12-month forecast

$47.40+155.9% upside

Based on 11 price targets given in the last 3 months, the average target is $47.40, the highest $59.00, the lowest $29.00. The average is +155.9% from the last price of $18.52.

$20.00$40.00$60.00Jan 26AprJulOctJan 27AprJulOctHigh$59.00Average$47.40Low$29.00
Highest target $59.00 Average target $47.40 Lowest target $29.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% Barclays $59.00 Buy +218.6% Reiterated 30.09.26on TipRanks 05:25 −0.3%next day −4.1% · 5 days −8.7%
Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% Raymond James $50.00 Buy +170.0% Reiterated 23.09.26on TipRanks Sep 24 03:25 −8.4%next day −3.4% · 5 days −5.2%
Mazahir Alimohamed★★★★★★★★★★#9079 · hits 50% · avg −1.5% Oppenheimer $50.00 → $40.00−20.0% Buy +116.0% Reiterated 22.09.26on TipRanks 08:00 −0.3%next day −8.4% · 5 days −12.9%
John Newman★★★★★★★★★★#3035 · hits 44% · avg +4.1% Canaccord Genuity $50.00 Buy +170.0% Reiterated 22.09.26on TipRanks 07:10 −0.3%next day −8.4% · 5 days −12.9%
Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% H.C. Wainwright $30.00 → $29.00−3.3% Buy +56.6% Reiterated 22.09.26on TipRanks 06:20 −0.3%next day −8.4% · 5 days −12.9%
Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% Wedbush $53.00 Buy +186.2% Reiterated 11.09.26on TipRanks Oct 1 10:25 −7.3%next day +14.2% · 5 days +16.9%
Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% JonesTrading $56.00 Buy +202.4% Reiterated 10.09.26on TipRanks 07:50 +7.6%next day −7.3% · 5 days +3.2%
Sami Corwin★★★★★★★★★★#511 · hits 55% · avg +18.5% William Blair — Buy — Reiterated 09.09.26on TipRanks 10:55 −17.2%next day +7.6% · 5 days +11.7%
Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% Piper Sandler $56.00 Buy +202.4% Reiterated 08.09.26on TipRanks 07:25 −6.2%next day −17.2% · 5 days −3.7%
Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% Bank of America Securities $39.00 Buy +110.6% Reiterated 08.09.26on TipRanks 06:25 −6.2%next day −17.2% · 5 days −3.7%
Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% Jefferies $44.00 → $42.00−4.5% Buy +126.8% Reiterated 05.08.26on TipRanks 15:20 −20.8%next day +5.0% · 5 days −1.9%
Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% Wedbush $53.00 Buy +186.2% Reiterated 05.08.26on TipRanks 10:35 −20.8%next day +5.0% · 5 days −1.9%
Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% Wolfe Research — Hold — Initiated 19.05.26on TipRanks 06:15 −4.6%next day −2.1% · 5 days −4.1%
Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% TD Cowen — Buy — Reiterated 13.05.26on TipRanks 11:35 +3.2%next day +0.1% · 5 days −7.6%
Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% Guggenheim $54.00 Buy +191.6% Initiated 15.04.26on TipRanks Apr 14 16:20 −1.6%next day +0.2% · 5 days +5.2%
Li Watsek★★★★★★★★★★#11877 · hits 39% · avg −9.1% Cantor Fitzgerald — Buy — Reiterated 04.03.26on TipRanks Mar 5 01:25 +6.1%next day −1.5% · 5 days +4.9%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Tyra Bioscience

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Mitchell Kapoor★★★★★★★★★★H.C. Wainwright · #1086
Hits 45%215 of 481 Average return +12.2%
1 year Mitchell Kapoor★★★★★★★★★★H.C. Wainwright · #1086
Hits 45%215 of 481 Average return +12.2%
2 years Tyler Van Buren★★★★★★★★★★TD Cowen · #42
Hits 64%312 of 490 Average return +38.8%

Most profitable

3 months Mitchell Kapoor★★★★★★★★★★H.C. Wainwright · #1086
Hits 45%215 of 481 Average return +12.2%
1 year Jason Zemansky★★★★★★★★★★Bank of America Securities · #467
Hits 60%151 of 251 Average return +21.6%
2 years Tyler Van Buren★★★★★★★★★★TD Cowen · #42
Hits 64%312 of 490 Average return +38.8%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $47.40 at a price of $21.87 (+116.7%); now: $47.40 at $18.52 (+155.9%).

$20.00$30.00$40.00Sep 15Oct 1Oct 15Top analysts$45.83Average target$47.40Price$18.52

PriceAverage targetTop analysts’ target

Recommendation trend

010203091Oct 2561Nov41Dec53Jan 2698Feb1113Mar1215Apr7201May12161Jun15131Jul213Aug246Sep195Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy71215212419
Buy201613365
Hold111000
Sell000000

Earnings and sales forecast

Next report: 11.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.67 (from $-0.76 to $-0.47). Last quarter: $-0.69.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Tyra Bioscience
  • CEO: Todd Harris
  • Employees: 87
  • 2656 State Street, Carlsbad, CA, 92008, US
  • www.tyra.bio

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

Data from the stock’s TipRanks forecast page, read 59 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗